Biogen’s FDA Approval Takes Center Stage

By Brandon Rakszawski, Senior ETF Product Manager The Morningstar Wide Moat Focus Index (the “Moat Index” or “Index”) underperformed the S&P 500® Index in June (1.15% vs. 2.33%, respectively). Despite the modest underperformance, the Index remains ahead of the S&P 500 Index by over 4.5%...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.